

Epoetin alfa– Biosimilar Insight, 2022

<https://marketpublishers.com/r/E7AB6DDE1146EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: E7AB6DDE1146EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Epoetin alfa– Biosimilar 2022," report provides comprehensive insights about 15+ companies and 20+ marketed and pipeline drugs in Epoetin alfa Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Epoetin alfa Understanding

Epoetin alfa: Overview

Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein manufactured by recombinant DNA technology. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin. Epogen (epoetin alfa) injection for intravenous or subcutaneous administration is formulated as a sterile, clear, colorless liquid in vials in multiple formulations.

Epoetin alfa Biosimilars: Drugs Chapters

This segment of the Epoetin alfa report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, Phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Epoetin alfa Biosimilars: Marketed Drugs

Binocrit: Sandoz

Binocrit (epoetin alfa) is a prescription medicine that stimulates the bone marrow to produce red blood cells. In April 2016, Sandoz announced that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit's (epoetin alfa) nephrology indication.

Epoimmun: Biosidus

Epoimmun is a synthetic form of human erythropoietin, used to treat anemia. Biosidus recombinant human erythropoietin is their flagship product which is obtained by mass cell culture of genetically modified mammalian cells.

Further product details are provided in the report.....

Epoetin alfa Biosimilars: Emerging Drugs

UB 851: UBI Pharma

UB-851 is a recombinant human EPO biosimilar. Its highly glycosylated structure, with sialic acid content being the key factor for the in vivo half-life of EPO, makes the product development challenging. Unlike small molecule drugs, biosimilars have complicated structures and large molecular weights. The bioactivity, safety, and efficacy of biosimilars are closely related to the manufacturing process, which is very difficult to replicate.

Further product details are provided in the report.....

Epoetin alfa: Therapeutic Assessment

This segment of the report provides insights about the different Epoetin alfa biosimilars segregated based on following parameters that define the scope of the report, such as:

Major Players in Epoetin alfa

There are approx. 15+ key companies which are developing the therapies for Epoetin alfa.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Marketed stage products

Late stage products (BLA Filed and Phase III)

Mid-stage products (Phase II and

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Epoetin alfa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibodies

Peptide

Protein

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Epoetin alfa: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Epoetin alfa biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Epoetin alfa biosimilar drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Epoetin alfa R&D. The therapies under development are focused on novel approaches to treat/improve Epoetin alfa.

In May 2018, Pfizer announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT (epoetin alfa-epbx), a biosimilar to Epogen and Procrit (epoetin alfa)¹, for all indications of the reference product. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) to be approved in the US.

In August 2018, Stada announced that it is increasing its presence in the biosimilar sphere by becoming the majority shareholder in Bioceuticals, a venture capital-funded organization created by Stada to carry out its biosimilar programs.

Epoetin alfa Biosimilars Report Insights

Epoetin alfa Biosimilar Pipeline Analysis

Therapeutic Assessment

Sales Assessment

Unmet Needs

Impact of Drugs

Epoetin alfa Biosimilar Report Assessment

Marketed Product profiles

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Sales Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Epoetin alfa Biosimilars?

How many Epoetin alfa biosimilars are developed by each company?

How many emerging biosimilars are in mid-stage, and late-stage?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Epoetin alfa biosimilars therapeutics?

What are the clinical studies going on for Epoetin alfa biosimilars and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Zydus Cadila

Wockhardt

UBI Pharma

Sun Pharmaceutical Industries

Stada Arzneimittel

Sedico

Sandoz

Reliance Life Sciences

Pfizer (Hospira)

Duopharma

Nanogen

Medice Arzneimittel P?tter

LG Chem

Hexal

Emcure

Dragon Pharmaceutical

Claris Lifesciences

Blau Farmaceutica

Biosidus

Biocon

Biocad

Apotex

Amega Bitoech

Johnson & Johnson

PanGen

Key Products

EPO

Wepox

UB-851

Ceriton

Silapo

Epoetin 2000 I.U.

Binocrit

Epostim

ReliPoietin

Retacrit

Erisa (PDA10)

Nanokine

Abseamed

Espogen

Epoetin alfa Hexal

Epofer

BR 05001

Epotin

Eritromax

Epoimmun

Erypro

Erythropoietin alfa biosimilar

APO-EPO

Recombinant erythropoietin

Epoetin alfa - ProLease

PDA 10

Contents

1. KEY INSIGHTS

2. EPOETIN ALFA BIOSIMILARS: SNAPSHOT

3. EXECUTIVE SUMMARY

3.1. Overview

3.2. The Basics of Biologics.

3.3. Biosimilars are not the Same as Generic Drugs

3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?

3.5. What Patients Need to Know About Biosimilars

4. REGULATORY OUTLOOK FOR BIOSIMILARS

4.1. North America

4.1.1. US

4.1.2. Canada

4.2. Europe

4.3. Asia Pacific

4.3.1. China

4.3.2. India

4.3.3. Japan

4.3.4. South Korea

4.3.5. Australia

4.4. Rest Of The World

4.4.1. Brazil

4.4.2. Mexico

4.4.3. Argentina

4.4.4. Saudi Arabia

*More Countries would be added in the final report

5. EPOETIN ALFA (REFERENCE PRODUCT: EPOGEN)

5.1. Product Overview

5.2. Indications

5.3. Mechanism of Action

5.4. Dosage and Administration

- 5.5. Dosage and Strengths
- 5.6. Dose Modification
- 5.7. Route of Synthesis
- 5.8. Pharmacology
- 5.9. Pharmacodynamics
- 5.10. Pharmacokinetics
- 5.11. Adverse Reactions
- 5.12. Product Snapshot
- 5.13. Development Milestones

6. REGULATORY MILESTONES

- 6.1. Approvals
- 6.2. Research and Development
- 6.3. Clinical Trials Information
- 6.4. Safety and Efficacy

7. EPOGEN BIOSIMILAR: EMERGING OPPORTUNITIES

8. EPOETIN ALFA: BIOSIMILARS ASSESSMENT

- 8.1. Assessment by Product Type
- 8.2. Assessment by Route of Administration
- 8.3. Assessment by Molecule type
- 8.4. Sales Assessment

9. EPOETIN ALFA BIOSIMILARS PROFILES: BY COMPANY

- 9.1.1. PanGen Biotech
 - 9.1.1.1. Erisa (PDA10): PanGen Biotech/Duopharma
 - 9.1.1.1.1. Product Information
 - 9.1.1.1.2. Research and Development
 - 9.1.1.1.3. Other Development Activities
 - 9.1.1.1.4. General Description Table
 - 9.1.2. Reliance Life Sciences
 - 9.1.2.1. Epostim: Reliance Life Sciences
 - 9.1.2.1.1. Product Information
 - 9.1.2.1.2. Research and Development
 - 9.1.2.1.3. Other Development Activities

9.1.2.1.4. General Description Table

9.1.2.2. ReliPoietin: Reliance Life Sciences

9.1.2.2.1. Product Information

9.1.2.2.2. Research and Development

9.1.2.2.3. Other Development Activities

9.1.2.2.4. General Description Table

*More Companies and products would be added in the final report

10. EPOETIN ALFA BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY

11. EPOETIN ALFA BIOSIMILARS: COMPETITIVE LANDSCAPE

11.1.1. Overview

11.1.2. Market Share Analysis

11.1.3. Competitive Scenario

11.1.3.1. Product Launches and approval

11.1.3.2. Partnerships, Collaborations and Agreements

11.1.3.3. Acquisitions

11.1.3.4. Expansions

11.1.3.5. Patent Expiration of Biologics

*More information would be added in the final report

12. MARKET DRIVERS

13. MARKET BARRIERS

14. SWOT ANALYSIS

15. APPENDIX

15.1. Research Methodology

15.1.1. Coverage

15.1.2. Secondary Research

16. BIBLIOGRAPHY

17. DELVEINSIGHT CAPABILITIES

18. DISCLAIMER

19. ABOUT DELVEINSIGHT

I would like to order

Product name: Epoetin alfa– Biosimilar Insight, 2022

Product link: <https://marketpublishers.com/r/E7AB6DDE1146EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E7AB6DDE1146EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970